| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
|
J Am Dent Assoc, Vol 139, No 1, 32-40.
© 2008 American Dental Association |  |
COVER STORY |
Background. The authors determined incidence of osteonecrosis of the jaw (ONJ) in a large, prospective three-year clinical trial of zoledronic acid in women with postmenopausal osteoporosis (PMO).
Methods. A total of 7,714 women with PMO received intravenous zoledronic acid 5 mg or a placebo. No spontaneous reports of ONJ were received. An independent, blinded adjudication committee searched the trial’s adverse event database by using 60 terms. On an ongoing basis, the committee reviewed the identified events, and it defined ONJ as exposed bone in the maxillofacial area with delayed healing for more than six weeks despite appropriate care.
Results. One participant who received a placebo and one participant who received zoledronic acid experienced delayed healing associated with infection. Both conditions resolved after antibiotic therapy, débridement or both.
Conclusion. The occurrence of ONJ is rare in a PMO population, and delayed healing of lesions can occur with and without bisphosphonate use over three years.
Clinical Implications. The low incidence of ONJ must be assessed in the context of the clinical benefit of zoledronic acid therapy in reducing hip, vertebral and nonvertebral fractures in this at-risk population. There is no evidence to suggest that healthy patients with osteoporosis who are receiving bisphosphonates require any special treatment beyond routine dental care or to support altering standard treatment practices.
Abbreviations: ASBMR: American Society for Bone and Mineral Research • HORIZON-PFT: Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly Pivotal Fracture Trial • MedDRA: Medical Dictionary for Regulatory Activities • ONJ: Osteonecrosis of the jaw • PMO: Postmenopausal osteoporosis
This article has been cited by other articles:
|
|
 |
|
  M. C. A. BUENCAMINO, L. PALOMO, and H. L. THACKER How menopause affects oral health, and what we can do about it Cleveland Clinic Journal of Medicine, August 1, 2009; 76(8): 467 - 475. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Pazianas, R. G. G. Russell, and I. Fogelman Osteonecrosis of the Jaw: More Heat Than Light J. Nucl. Med., January 1, 2009; 50(1): 6 - 7. [Full Text] [PDF]
|
|
|
|
 |
|
 Annual {blacktriangledown}zoledronic acid for osteoporosis DTB, December 1, 2008; 46(12): 93 - 96. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. CAREY and L. PALOMO Bisphosphonates and osteonecrosis of the jaw: Innocent association or significant risk? Cleveland Clinic Journal of Medicine, December 1, 2008; 75(12): 871 - 879. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Edwards, J. W. Hellstein, P. L. Jacobsen, S. Kaltman, A. Mariotti, C. A. Migliorati, and for the American Dental Association Council on Sci Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: An advisory statement from the American Dental Association Council on Scientific Affairs J Am Dent Assoc, December 1, 2008; 139(12): 1674 - 1677. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. M. Cartsos, S. Zhu, and A. I. Zavras Authors' response J Am Dent Assoc, May 1, 2008; 139(5): 536 - 537. [Full Text] [PDF]
|
|
|
|
 |
|
 Oral Bisphosphonates and Oral Health Journal Watch Women's Health, February 28, 2008; 2008(228): 2 - 2. [Full Text]
|
|
|
|
|
|
M. Glick Closing in on the Puzzle of ONJ J Am Dent Assoc, January 1, 2008; 139(1): 12 - 15. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
